Coherus Stock Extends Impressive Rally on Drug Sales

The stock is pacing for its fifth straight win today

Digital Content Manager
Apr 8, 2019 at 10:03 AM
facebook X logo linkedin


The drug maker Coherus BioSciences Inc (NASDAQ:CHRS) is near the top of the Nasdaq today, after the company announced late Friday that preliminary sales of its biosimilar UDENYCA -- used in patients receiving myelosuppressive chemotherapy -- are expected to be between $36 million and $38 million. In response, CHRS stock is up 13.5% at $16.61. 

The security has been on the rise lately, after stringing together four consecutive wins last week -- set for its fifth day in the black today. Looking at the charts, CHRS has nearly doubled off its early January low of $8.32. Today's gap has the shares above short-term resistance in the $15.50 area, and trading in territory not seen since early October.

The news has analysts paying attention, too. J.P. Morgan Securities just lifted its target price to $25 from $22. Sentiment surrounding the stock has already been quite bullish, however. Currently, all five analysts consider CHRS stock a "strong buy," and the consensus 12-month target price of $29 represents a roughly 80.5% premium to current levels. 

Short sellers have started hitting the exits, with short interest down 3.7% in the latest reporting period. Short interest still represents a healthy 17.5% of the stock's available float, though. At CHRS' annual daily pace of trading, it would take over two weeks to cover these pessimistic positions -- which may be contributing to today's outsized gains. 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI